Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Purchases 22,192 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were bought at an average price of $2.27 per share, with a total value of $50,375.84. Following the completion of the acquisition, the director now directly owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This represents a 45.62 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Perspective Therapeutics Trading Down 8.0 %

Shares of NYSE:CATX opened at $1.96 on Wednesday. The firm’s 50 day moving average price is $2.88 and its 200-day moving average price is $6.10. Perspective Therapeutics, Inc. has a twelve month low of $1.90 and a twelve month high of $19.05.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CATX. The Manufacturers Life Insurance Company raised its stake in Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after acquiring an additional 1,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after purchasing an additional 3,211 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Perspective Therapeutics by 7.4% in the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock worth $163,000 after purchasing an additional 3,529 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock valued at $303,000 after buying an additional 4,075 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Perspective Therapeutics by 3.4% in the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after buying an additional 4,693 shares during the period. Institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on CATX shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.